Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncolys BioPharma's revenue for the
three
months ended in Jun. 2026 was 円0.00 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was 円31.64 Mil.
Oncolys BioPharma's Revenue per Share for the
three
months ended in Jun. 2026 was 円0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was 円1.26.
Warning Sign:
Oncolys BioPharma Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Oncolys BioPharma was -16.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -73.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -54.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -21.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Oncolys BioPharma's highest 3-Year average Revenue per Share Growth Rate was 380.10% per year. The lowest was -73.00% per year. And the median was -0.70% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Oncolys BioPharma Revenue Related Terms
Oncolys BioPharma Revenue Historical Data
* Premium members only.
The historical data trend for Oncolys BioPharma's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oncolys BioPharma's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncolys BioPharma Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncolys BioPharma's Revenue distribution charts can be found below:
* The bar in red indicates where Oncolys BioPharma's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円31.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncolys BioPharma (TSE:4588) has a Revenue of 円31.64 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Oncolys BioPharma and its competitors.
Is Oncolys BioPharma's Revenue too high?
Oncolys BioPharma's current Revenue is 円31.64 Mil. Overall, Oncolys BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's Revenue compare to VRTX and REGN?
Oncolys BioPharma's Revenue of 円31.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Oncolys BioPharma and its competitors. Oncolys BioPharma's current Revenue is 円31.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円355.30, compared to a current price of 円3,560.00 — trading 902% above its estimated fair value. The current Revenue is 円31.64 Mil. Oncolys BioPharma's overall GF Score™ is 40/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current Revenue is 円31.64 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?
Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued.
The current stock price of 円3,560.00 is trading 902% above its estimated GF Value™ of 円355.30.
GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.
Key valuation signals for TSE:4588:
Revenue: 円31.64 Mil
GF Value™: 円355.30 vs. price of 円3,560.00 (902% above fair value)
No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
40GF Score
Get the complete analysis for TSE:4588
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4588 has been successfully added to your 
